Bioequivalent formulation for the fixed-dose regimen of Truvada and TMC278 finalized.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D017326:Clinical Trials, Phase III as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D009570:Nitriles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011743:Pyrimidines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D000068696:Rilpivirine; D013810:Therapeutic Equivalency
D019380:Anti-HIV Agents; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D009570:Nitriles; D009943:Organophosphorus Compounds; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; D003841:Deoxycytidine; D000068696:Rilpivirine